01420nas a2200229   4500000000100000008004100001260001600042653001500058653001300073653002000086653002400106100001500130700001200145700001300157700001100170245005800181856026000239300001100499490000700510520065900517022001401176       2025                            d  bElsevier BV10aIvermectin10aCovid-1910aAnti-helminthic10aGynecologic cancers1 aMujumdar V1 aHuang M1 aSmith LC1 aMusa F00aIvermectin and gynecologic cancer: What’s the data?  uhttps://pdf.sciencedirectassets.com/311234/1-s2.0-S2352578925X00047/1-s2.0-S2352578925001286/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEOj%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG9G%2B0YitC30FMja3b%2Bij0Zvho9WKM4tnKjTOIcSC1whAiBNYP7b14uy  a1018030 v603 a<h2>Highlights</h2>

<p>•</p>

<p>Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.</p>

<p>•</p>

<p>The data on ivermectin as a gynecologic cancer-fighting compound is lacking.</p>

<p>•</p>

<p>Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.</p>

<p>•</p>

<p>We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.</p>

<p>•</p>

<p>We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.</p>
  a2352-5789